Stay Cool with Divigel®
Divigel® is FDA-approved to treat moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause.

Proven Relief From Hot Flashes and Night Sweats
- Eliminated nearly 90% of hot flashes by 12 weeks with 1 mg/day.1
- Reduced hot flashes by nearly HALF in as little as 2 weeks (1 mg/day).1
- Comes in five dose strengths, including the lowest FDA approved dose.2
- At the lowest dose (0.25 mg/day) Divigel® eliminated about 70% of hot flashes in 12 weeks.1
The FDA recommends the lowest effective dose with any estrogen therapy.2,3 Only Divigel® offers the lowest dose of topical estrogen gel or spray available for hot flashes (0.25 mg/day estradiol)2
Use estrogen-alone, or in combination with progestin, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

Cool, Discreet Gel
- Divigel® is a gel that leaves no sticky residue.
- It’s invisible and odorless when dry. Nobody knows you’re wearing it.
- It’s a concentrated estradiol gel, so only a small amount is needed for big relief.

Easy to Use and Convenient
- A small amount of Divigel® is applied once daily to the upper thigh.
- The gel comes in small, discreet, portable packets that are easy to use at home and great for travel.
- Premeasured, daily packets ensure precise, accurate dosing.
- Divigel® becomes part of your daily personal care routine.
DELIVERED THROUGH THE SKIN
Although the clinical significance has not been determined, estradiol from Divigel® does not undergo first pass metabolism.
DIVIGEL® TOPICAL GEL







ORAL TREATMENTS








IS DIVIGEL® FOR YOU?
Ask your doctor for a free sample of Divigel® to help you get started. Each sample comes with 7 days of therapy and a travel case. Your doctor can order samples here.
REFERENCES
1. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009;16(1):132-140.
2. Orange Book: Approved Drug Products with Therapeutic equivalence Evaluations. U.S. Food & Drug Administration. Accessed February 13, 2020. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
3. US Food and Drug Administration. Menopause. Updated August 22, 2019. Accessed February 13, 2020. https://www.fda.gov/consumers/womens-health-topics/menopause